Requires health insurance coverage of prescribed anti-obesity medication.
Impact
The legislation will affect various health insurance plans including individual policies, small employer plans, and contracts managed by state health commissions. By requiring these plans to cover FDA-approved anti-obesity medications to the same extent as other medical conditions, A1207 aims to enhance the treatment landscape for obesity. Given the alarming statistics regarding obesity—affecting nearly one-third of adults and 17% of children aged 2 to 19—this bill seeks to mitigate the associated health risks through accessible treatment options.
Summary
Assembly Bill A1207 mandates health insurance carriers in New Jersey to provide coverage for prescribed anti-obesity medications. This requirement aims to equalize coverage for obesity treatment with that of other medical conditions, reinforcing the significance of addressing obesity as a critical healthcare issue. The legislation aligns with the recognition of obesity as a disease by the American Medical Association since 2013, and it highlights the need for increased access to effective treatment options for individuals affected by obesity.
Contention
The primary point of contention surrounding A1207 may center on how this mandate could impact insurance premiums and the operational procedures of healthcare providers. While proponents advocate for improved health outcomes through greater accessibility to weight management medications, opponents may raise concerns regarding the financial implications for insurance carriers and their subscribers. Discussions could also include the appropriateness of governmental mandates in medical coverage decisions, reflecting broader debates on healthcare policy in America.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.
Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.